血脂比值指标在心血管疾病风险预估中的研究进展-国际临床研究杂志-CSCIED科技核心评价数据库-手机版

血脂比值指标在心血管疾病风险预估中的研究进展

Research progress on the role of lipid ratio indicators in the estimation of cardiovascular disease risk

ES评分 0 浏览量：55 下载量：0

DOI	10.12208/j.ijcr.20250184
刊名	国际临床研究杂志 International Journal of Clinical Research
年，卷(期)	2025, 9(4)
作者	李雅甜¹,李宏伟¹,李继舟¹,张晔²,杨红玲²*,
作者单位	1 大理大学临床医学院云南大理,2 云南省第三人民医院云南昆明
摘要	血脂异常是引发心血管疾病（CVD）的关键因素之一，其中低密度脂蛋白胆固醇（LDL-C）水平长期以来被视为心血管疾病风险评估的核心指标。然而，近年来的研究表明，血脂比值指标在预测心血管疾病风险方面可能比单一血脂指标（如LDL-C）更具优势。这些血脂比值指标，如载脂蛋白B与载脂蛋白A1比值（ApoB/ApoA1）、非高密度脂蛋白胆固醇与高密度脂蛋白胆固醇比值（non-HDL-C/HDL-C）、残余胆固醇与高密度脂蛋白胆固醇比值（RC/HDL-C）以及低密度脂蛋白胆固醇与高密度脂蛋白胆固醇比值（LDL-C/HDL-C），在临床应用中可为心血管疾病风险评估提供更精确的工具。
Abstract	Dyslipidemia is one of the key factors contributing to cardiovascular diseases (CVD), with low-density lipoprotein cholesterol (LDL-C) levels long regarded as a central metric for assessing cardiovascular risk. However, recent studies suggest that lipid ratio indices may offer superior predictive value for cardiovascular risk compared to single lipid metrics such as LDL-C. These lipid ratio indices, including the apolipoprotein B to apolipoprotein A1 ratio (ApoB/ApoA1), non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (non-HDL-C/HDL-C), remnant cholesterol to high-density lipoprotein cholesterol ratio (RC/HDL-C), and low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (LDL-C/HDL-C), provide more precise tools for cardiovascular risk assessment in clinical practice.
关键词	血脂比值指标；心血管疾病；预测
KeyWord	Lipid ratio indices, Cardiovascular diseases, Risk prediction
基金项目
页码	50-55

参考文献
相关文献

[1] DISEASES N C F C, HEALTH T W C O T R O C, CHINA D I. 中国心血管健康与疾病报告2023概要
[J]. 中国循环杂志, 2024, 39(07): 625-60.
[2] LIU J Q, LI W X, ZHENG J J, et al. Gain and loss events in the evolution of the apolipoprotein family in vertebrata
[J]. BMC Evol Biol, 2019, 19(1): 209.
[3] RADFORD-SMITH D E, YATES A G, RIZVI L, et al. HDL and LDL have distinct, opposing effects on LPS-induced brain inflammation
[J]. Lipids Health Dis, 2023, 22(1): 54.
[4] 林满芳. 脂类测定与老年动脉粥样硬化及冠心病的相关性研究
[J]. 实用心脑肺血管病杂志, 2013, 21(01): 8-9.
[5] 中华医学会检验医学分会, 中国医师协会检验医师分会, 中国生物化学与分子生物学会脂质与脂蛋白专业委员会, et al. 中国临床血脂检测指南
[J]. 中华检验医学杂志, 2022, 45(10): 1017-33.
[6] GARí-LLANES M, GARCíA-NóBREGA Y, CHáVEZ-GONZáLEZ E, et al. Biochemical Markers and Hypertension in Children
[J]. MEDICC Rev, 2019, 21(2-3): 10-5.
[7] DOONAN L M, FISHER E A, BRODSKY J L. Can modulators of apolipoproteinB biogenesis serve as an alternate target for cholesterol-lowering drugs?
[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2018, 1863(7): 762-71.
[8] DING M, ZHENG L, LI Q F, et al. Exercise-Training Regulates Apolipoprotein B in Drosophila to Improve HFD-Mediated Cardiac Function Damage and Low Exercise Capacity
[J]. Front Physiol, 2021, 12: 650959.
[9] 王宏宇, 付茜, 苏福祥. 载脂蛋白B/载脂蛋白A1比值与急性冠脉综合征患者冠状动脉多支病变及斑块易损性的相关性
[J]. 中国医科大学学报, 2022, 51(07): 577-82.
[10] DENG F, LI D, LEI L, et al. Association between apolipoprotein B/A1 ratio and coronary plaque vulnerability in patients with atherosclerotic cardiovascular disease: an intravascular optical coherence tomography study
[J]. Cardiovasc Diabetol, 2021, 20(1): 188.
[11] TIAN M, LI R, SHAN Z, et al. Comparison of Apolipoprotein B/A1 ratio, Framingham risk score and TC/HDL-c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention
[J]. Lipids Health Dis, 2019, 18(1): 202.
[12] 付琳, 王敏, 李瑾. 冠心病病人载脂蛋白B/载脂蛋白A1、胱抑素C、血清胆红素水平变化及其与冠状动脉病变严重程度的相关性
[J]. 中西医结合心脑血管病杂志, 2022, 20(07): 1287-92.
[13] LITING P, GUOPING L, ZHENYUE C. Apolipoprotein B/apolipoprotein A1 ratio and non-high-density lipoprotein cholesterol. Predictive value for CHD severity and prognostic utility in CHD patients
[J]. Herz, 2015, 40 Suppl 1: 1-7.
[14] CHEN T, YANG M. Apo A1/Apo B ratio and acute coronary syndrome among peritoneal dialysis patients
[J]. Ren Fail, 2021, 43(1): 737-42.
[15] WANG X, WANG Z, LI B, et al. Prognosis evaluation of universal acute coronary syndrome: the interplay between SYNTAX score and ApoB/ApoA1
[J]. BMC Cardiovasc Disord, 2020, 20(1): 293.
[16] YUSUF S, HAWKEN S, OUNPUU S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
[J]. Lancet, 2004, 364(9438): 937-52.
[17] PIZOŃ T, RAJZER M, WOJCIECHOWSKA W, et al. The relationship between plasma renin activity and serum lipid profiles in patients with primary arterial hypertension
[J]. J Renin Angiotensin Aldosterone Syst, 2018, 19(4): 1470320318810022.
[18] BRUNNER F J, WALDEYER C, OJEDA F, et al. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium
[J]. Lancet, 2019, 394(10215): 2173-83.
[19] LIU J, SEMPOS C T, DONAHUE R P, et al. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease
[J]. Am J Cardiol, 2006, 98(10): 1363-8.
[20] BOEKHOLDT S M, ARSENAULT B J, MORA S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis
[J]. Jama, 2012, 307(12): 1302-9.
[21] WONGCHAROEN W, SUTTHIWUTTHICHAI S, GUNAPARN S, et al. Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol? : a retrospective study
[J]. BMC Cardiovasc Disord, 2017, 17(1): 10.
[22] ABEDI F, SADEGHI M, OMIDKHODA N, et al. HDL-cholesterol concentration and its association with coronary artery calcification: a systematic review and meta-analysis
[J]. Lipids Health Dis, 2023, 22(1): 60.
[23] GORDON T, CASTELLI W P, HJORTLAND M C, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study
[J]. Am J Med, 1977, 62(5): 707-14.
[24] GORDON D J, PROBSTFIELD J L, GARRISON R J, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies
[J]. Circulation, 1989, 79(1): 8-15.
[25] IANNUZZI A, GIALLAURIA F, GENTILE M, et al. Association between Non-HDL-C/HDL-C Ratio and Carotid Intima-Media Thickness in Post-Menopausal Women
[J]. J Clin Med, 2021, 11(1).
[26] LI T, YUAN D, WANG P, et al. Associations of lipid measures with total occlusion in patients with established coronary artery disease: a cross-sectional study
[J]. Lipids Health Dis, 2022, 21(1): 118.
[27] SHI J, ZHANG H Y, WANG D Y, et al.
[Associations between various lipid components and premature myocardial infarction: a cross-sectional study]
[J]. Zhonghua Xin Xue Guan Bing Za Zhi, 2023, 51(3): 278-87.
[28] MAO Q, ZHAO J, ZHAO X. Association of non-HDL-C-to-HDL-C ratio with coronary lesions and its prognostic performance in first-onset NSTEMI
[J]. Biomark Med, 2023, 17(1): 29-39.
[29] LIU J, ZHAO L, ZHANG Y, et al. A higher non-HDL-C/HDL-C ratio was associated with an increased risk of progression of nonculprit coronary lesion in patients with acute coronary syndrome undergoing percutaneous coronary intervention
[J]. Clin Cardiol, 2024, 47(2): e24243.
[30] NORDESTGAARD B G, BENN M, SCHNOHR P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women
[J]. Jama, 2007, 298(3): 299-308.
[31] LüTJOHANN D, KLöR H U, STELLAARD F. Measurement of Serum Low Density Lipoprotein Cholesterol and Triglyceride-Rich Remnant Cholesterol as Independent Predictors of Atherosclerotic Cardiovascular Disease: Possibilities and Limitations
[J]. Nutrients, 2023, 15(9).
[32] VARBO A, BENN M, TYBJæRG-HANSEN A, et al. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation
[J]. Circulation, 2013, 128(12): 1298-309.
[33] VARBO A, BENN M, TYBJæRG-HANSEN A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease
[J]. J Am Coll Cardiol, 2013, 61(4): 427-36.
[34] CAO Y X, ZHANG H W, JIN J L, et al. The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes
[J]. Cardiovasc Diabetol, 2020, 19(1): 104.
[35] MASUOKA H, ISHIKURA K, KAMEI S, et al. Predictive value of remnant-like particles cholesterol/high-density lipoprotein cholesterol ratio as a new indicator of coronary artery disease
[J]. Am Heart J, 1998, 136(2): 226-30.
[36] YU D, WANG Z, ZHANG X, et al. Remnant Cholesterol and Cardiovascular Mortality in Patients With Type 2 Diabetes and Incident Diabetic Nephropathy
[J]. J Clin Endocrinol Metab, 2021, 106(12): 3546-54.
[37] ZENG R X, LI S, ZHANG M Z, et al. Remnant cholesterol predicts periprocedural myocardial injury following percutaneous coronary intervention in poorly-controlled type 2 diabetes
[J]. J Cardiol, 2017, 70(2): 113-20.
[38] LAROSA J C, GRUNDY S M, WATERS D D, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease
[J]. N Engl J Med, 2005, 352(14): 1425-35.
[39] ODUNCU V, ERKOL A, KURT M, et al. The prognostic value of very low admission LDL-cholesterol levels in ST-segment elevation myocardial infarction compared in statin-pretreated and statin-naive patients undergoing primary percutaneous coronary intervention
[J]. Int J Cardiol, 2013, 167(2): 458-63.
[40] BARTER P, GENEST J. HDL cholesterol and ASCVD risk stratification: A debate
[J]. Atherosclerosis, 2019, 283: 7-12.
[41] SUN T, CHEN M, SHEN H, et al. Predictive value of LDL/HDL ratio in coronary atherosclerotic heart disease
[J]. BMC Cardiovasc Disord, 2022, 22(1): 273.
[42] WANG Y, ZHANG S S, LV Q B, et al. Comparison of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol for the prediction of thin-cap fibroatheroma determined by intravascular optical coherence tomography
[J]. J Geriatr Cardiol, 2020, 17(11): 666-73.
[43] JIANG S, FANG C, XU X, et al. Identification of High-Risk Coronary Lesions by 3-Vessel Optical Coherence Tomography
[J]. J Am Coll Cardiol, 2023, 81(13): 1217-30.
[44] ZHONG Z, HOU J, ZHANG Q, et al. Assessment of the LDL-C/HDL-C ratio as a predictor of one year clinical outcomes in patients with acute coronary syndromes after percutaneous coronary intervention and drug-eluting stent implantation
[J]. Lipids Health Dis, 2019, 18(1): 40.

引用本文

李雅甜,李宏伟,李继舟,张晔,杨红玲*. 血脂比值指标在心血管疾病风险预估中的研究进展 [J]. 国际临床研究杂志. 2025; 9; (4). 50 - 55.

文献评论

相关学者

相关机构